| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Ultrasound Guided Serratus Plane Block Thoracic Epidural Post Thoracotomy Pain | Procedure: Serratus anterior block Procedure: thoracic epidural | Not Applicable |
Show detailed description
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 60 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Ultrasound Guided Serratus Plane Block Versus Thoracic Epidural for Post Thoracotomy Pain: A Prospective Randomized Controlled Study |
| Actual Study Start Date : | June 10, 2019 |
| Actual Primary Completion Date : | May 1, 2020 |
| Actual Study Completion Date : | May 10, 2020 |
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: Thoracic epidural
thoracic epidural inserted at low thoracic level in sitting position then test dose will be administered to detect any complications then a bolus of 10 ml of 0.25% levobupivacaine 30 mint before skin incision followed by an infusion of 5 ml/hour of 0.125% levobupivacaine after surgery.
|
Procedure: thoracic epidural
In group I: thoracic epidural inserted at low thoracic level in sitting position then test dose will be administered to detect any complications then a bolus of 10 ml of 0.25% levobupivacaine 30 mint before skin incision followed by an infusion of 5 ml/hour of 0.125% levobupivacaine after surgery.
|
|
Experimental: Serratus plane block
after induction of anesthesia and Patients will be placed in the lateral position with the diseased side up. A linear ultrasound transducer (10-12 MHz) will be placed over the mid-axillary region of the thoracic cage in a sagittal plane. The rib will be counted inferiorly and laterally until the fifth rib is identified in the mid-axillary line. The following muscles will be identified easily overlying the fifth rib: the latissimus dorsi (superficial and posterior), teres major (superior) and serratus muscle (deep and inferior). The needle (22- G, 50 - mm Touhy needle) will be introduced in-plane with respect to the ultrasound probe targeting the plane superficial to the serratus muscle. Under continuous ultrasound guidance a bolus of 30 ml of 0.25% levobupivacaine 30 min before skin incision. At the end of surgery, surgeon will put the catheter deep to serratus muscle and get it out with chest tube and fix it followed by an infusion of 5 ml/hour of 0.125% Levobupivacaine.
|
Procedure: Serratus anterior block
after induction of anesthesia and Patients will be placed in the lateral position with the diseased side up. A linear ultrasound transducer (10-12 MHz) will be placed over the mid-axillary region of the thoracic cage in a sagittal plane. The rib will be counted inferiorly and laterally, until the fifth rib is identified in the mid-axillary line. The following muscles will be identified easily overlying the fifth rib: the latissimus dorsi (superficial and posterior), teres major (superior) and serratus muscle (deep and inferior). The needle (22- G, 50 - mm Touhy needle) will be introduced in-plane with respect to the ultrasound probe targeting the plane superficial to the serratus muscle. Under continuous ultrasound guidance a bolus of 30 ml of 0.25% levobupivacaine 30 mint before skin incision. At the end of surgery, surgeon will put the catheter deep to serratus muscle and get it out with chest tube and fix it followed by an infusion of 5 ml/hour of 0.125% Levobupivacaine.
|
| Ages Eligible for Study: | 20 Years to 60 Years (Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
| Egypt | |
| National Cancer Institute - Egypt | |
| Cairo, Egypt | |
| Tracking Information | |||||||
|---|---|---|---|---|---|---|---|
| First Submitted Date ICMJE | April 23, 2019 | ||||||
| First Posted Date ICMJE | May 1, 2019 | ||||||
| Last Update Posted Date | July 22, 2020 | ||||||
| Actual Study Start Date ICMJE | June 10, 2019 | ||||||
| Actual Primary Completion Date | May 1, 2020 (Final data collection date for primary outcome measure) | ||||||
| Current Primary Outcome Measures ICMJE |
Score of postoperative pain at rest (Visual Analogue Scale, VAS, pain score). [ Time Frame: 24 hours postoperative ] Scores are based on self-reported measures of symptoms that are recorded with a single handwritten mark placed at one point along the length of a 10-cm line that represents a continuum between the two ends of the scale-"no pain" on the left end (0 cm) of the scale and the "worst pain" on the right end of the scale (10 cm)
|
||||||
| Original Primary Outcome Measures ICMJE |
Postoperative pain at rest (Visual Analogue Scale, VAS, pain score). [ Time Frame: 24 hours postoperative ] Scores are based on self-reported measures of symptoms that are recorded with a single handwritten mark placed at one point along the length of a 10-cm line that represents a continuum between the two ends of the scale-"no pain" on the left end (0 cm) of the scale and the "worst pain" on the right end of the scale (10 cm)
|
||||||
| Change History | |||||||
| Current Secondary Outcome Measures ICMJE |
|
||||||
| Original Secondary Outcome Measures ICMJE |
|
||||||
| Current Other Pre-specified Outcome Measures | Not Provided | ||||||
| Original Other Pre-specified Outcome Measures | Not Provided | ||||||
| Descriptive Information | |||||||
| Brief Title ICMJE | Ultrasound Guided Serratus Plane Block Versus Thoracic Epidural for Post Thoracotomy Pain | ||||||
| Official Title ICMJE | Ultrasound Guided Serratus Plane Block Versus Thoracic Epidural for Post Thoracotomy Pain: A Prospective Randomized Controlled Study | ||||||
| Brief Summary | This study aims at comparing the effect of serratus plane block versus thoracic epidural in patients undergoing thoracotomy for lung cancer surgery regarding pain control and possible side effects. | ||||||
| Detailed Description |
Introduction: One of the most painful devastating surgical incisions is post-thoracotomy pain which can occur secondary to skin incision, damage to serratus anterior and intercostal muscles, rib retraction and injury of the intercostal nerves (1). It leads to pulmonary complications in the short term and chronic post-thoracotomy pain in the long term (2). The thoracic epidural is usually used as the reference analgesic approach for controlling thoracotomy pain (3) but it carries several risks and limitations (4). Serratus anterior plane block is performed by blocking the lateral cutaneous branches of the intercostal nerves (5) and can be a possible alternative to epidural block with lesser risks (6). Aim of the work This study aims at comparing the effect of serratus plane block versus thoracic epidural in patients undergoing thoracotomy for lung cancer surgery regarding pain control and possible side effects. Authors suggest that this technique is easy to perform, safe, effective with lesser side effects. Study Design A randomized controlled study. Methodology After approval of the institutional board ethical committee, written informed consent will be taken from the patients undergoing the study. Sixty patients between 20 to 60 years old undergoing thoracic surgery will be included in the study and randomly allocated into one of the two study groups: Group (I) 30 patients: will receive 10 mL bolus of levobupivacaine 0.25% 30 mint before skin incision followed by an infusion of 5 ml/hour of 0.125% levobupivacaine after surgery. Group (II) 30 patients: will receive 30 ml bolus of 0.25% levobupivacaine 30 mint before skin incision followed by an infusion of 5 ml/hour of 0.125% levobupivacaine after surgery. Interventions: Routine preoperative assessment will be conducted as standard (Complete blood count, liver, and kidney function tests, coagulation profile and chest x-ray) in addition to pulmonary function tests. Upon arrival to the holding area, all the patients will be monitored by standard monitoring (ECG, Pulse oximetry and non-invasive automated arterial blood pressure). Then all patients will be pre-medicated with midazolam (3-5 mg intravenous) after fixation of 20 G cannula. In group I: thoracic epidural inserted at a low thoracic level in sitting position then test dose will be administered to detect any complications, then a bolus of 10 ml of 0.25% levobupivacaine 30 mint before skin incision followed by an infusion of 5 ml/hour of 0.125% levobupivacaine after surgery. In group II: after induction of anesthesia and Patients will be placed in the lateral position with the diseased side up. A linear ultrasound transducer (10-12 MHz) will be placed over the mid-axillary region of the thoracic cage in a sagittal plane. The rib will be counted inferiorly and laterally until the fifth rib is identified in the mid-axillary line. The following muscles will be identified easily overlying the fifth rib: the latissimus dorsi (superficial and posterior), teres major (superior) and serratus muscle (deep and inferior). The needle (22- G, 50 - mm Touhy needle) will be introduced in-plane with respect to the ultrasound probe targeting the plane superficial to the serratus muscle. Under continuous ultrasound guidance a bolus of 30 ml of 0.25% levobupivacaine 30 mint before skin incision. At the end of the surgery, the surgeon will put the catheter deep to serratus muscle and get it out with chest tube and fix it followed by an infusion of 5 ml/hour of 0.125% levobupivacaine. Pain Management: Intraoperative: by bolus dose for both groups. To ensure adequate analgesia throughout the operation all patients will be closely observed and upon the appearance of signs of inadequate analgesia e.g. increase in heart rate or systolic blood pressure 20% above the baseline, fentanyl rescue doses of 0.5µ/kg will be supplemented and recorded. Postoperative: by continues infusion for both groups. All patients will have Intravenous paracetamol every 8 hours. Morphine 5mg intravenous will be given when the visual analogue scale (VAS) pain score becomes >3 as rescue analgesia. Sample size: The sample size was calculated based on the previous paper (7) estimating the difference in pain score at 24 h between 2 groups will be 2±2.1. Using power 80% and 5% significance level of 18 patients in each group will be sufficient to be able to reject the null hypothesis that the population means of the experimental and control groups are equal. This number is to be increased to 21 in each group to correct for non-parametric usage. Sample size calculation was achieved using Power and Sample Size Calculation Software Version 3.1.2 (Vanderbilt University, Nashville, Tennessee, USA). Statistical analysis: Data will be analyzed using Statistical Package for the Social Sciences (SPSS) win statistical package version 17. Parametric demographic data will be analyzed using student's t-test, Qualitative data will be compared using Chi-square test or Fisher's exact as appropriate. Numerical data will be described as mean and standard deviation (SD) or median and range as appropriate. While qualitative data will be described as frequency and percentage. P<0.05 will be considered statistically significant. |
||||||
| Study Type ICMJE | Interventional | ||||||
| Study Phase ICMJE | Not Applicable | ||||||
| Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment |
||||||
| Condition ICMJE |
|
||||||
| Intervention ICMJE |
|
||||||
| Study Arms ICMJE |
|
||||||
| Publications * | Not Provided | ||||||
|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||
| Recruitment Information | |||||||
| Recruitment Status ICMJE | Completed | ||||||
| Actual Enrollment ICMJE |
60 | ||||||
| Original Estimated Enrollment ICMJE | Same as current | ||||||
| Actual Study Completion Date ICMJE | May 10, 2020 | ||||||
| Actual Primary Completion Date | May 1, 2020 (Final data collection date for primary outcome measure) | ||||||
| Eligibility Criteria ICMJE |
Inclusion Criteria:
Exclusion Criteria:
|
||||||
| Sex/Gender ICMJE |
|
||||||
| Ages ICMJE | 20 Years to 60 Years (Adult) | ||||||
| Accepts Healthy Volunteers ICMJE | No | ||||||
| Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||||
| Listed Location Countries ICMJE | Egypt | ||||||
| Removed Location Countries | |||||||
| Administrative Information | |||||||
| NCT Number ICMJE | NCT03933592 | ||||||
| Other Study ID Numbers ICMJE | 201617026 | ||||||
| Has Data Monitoring Committee | Not Provided | ||||||
| U.S. FDA-regulated Product |
|
||||||
| IPD Sharing Statement ICMJE |
|
||||||
| Responsible Party | Mamdouhmahmoud, National Cancer Institute, Egypt | ||||||
| Study Sponsor ICMJE | National Cancer Institute, Egypt | ||||||
| Collaborators ICMJE | Not Provided | ||||||
| Investigators ICMJE | Not Provided | ||||||
| PRS Account | National Cancer Institute, Egypt | ||||||
| Verification Date | July 2020 | ||||||
|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |
|||||||